Literature DB >> 21507165

Medically refractory neurosarcoidosis treated with infliximab.

J Pereira1, N E Anderson, D McAuley, P Bergin, D Kilfoyle, J Fink.   

Abstract

Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21507165     DOI： 10.1111/j.1445-5994.2011.02457.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


  10 in total

1.  Long-term outcomes of refractory neurosarcoidosis treated with infliximab.

Authors:  Fleur Cohen Aubart; Diane Bouvry; Damien Galanaud; Caroline Dehais; Guillaume Mathey; Dimitri Psimaras; Julien Haroche; Corinne Pottier; Miguel Hie; Alexis Mathian; Hervé Devilliers; Hilario Nunes; Dominique Valeyre; Zahir Amoura
Journal:  J Neurol       Date:  2017-03-04       Impact factor: 4.849

Review 2.  A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature.

Authors:  Idanis Berrios; Adalia Jun-O'Connell; Sorina Ghiran; Carolina Ionete
Journal:  BMJ Case Rep       Date:  2015-07-06

3.  Refractory multisystem sarcoidosis responding to infliximab therapy.

Authors:  Adam P Croft; Deva Situnayake; Omer Khair; Gavin Giovanni; David Carruthers; Arul Sivaguru; Caroline Gordon
Journal:  Clin Rheumatol       Date:  2012-01-17       Impact factor: 2.980

Review 4.  Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

Authors:  Lindsay J Celada; Wonder P Drake
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

5.  Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis.

Authors:  Abdullah Sakkat; Gerard Cox; Nader Khalidi; Maggie Larche; Karen Beattie; Elisabetta A Renzoni; Nilesh Morar; Vasilis Kouranos; Martin Kolb; Nathan Hambly
Journal:  Respir Res       Date:  2022-03-09

6.  Neurosarcoidosis.

Authors:  Kenkichi Nozaki; Marc A Judson
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 7.  Headaches related to rheumatologic disease.

Authors:  Noa Schwartz; Hal J Mitnick; Johannes Nowatzky
Journal:  Curr Pain Headache Rep       Date:  2013-12

8.  Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations.

Authors:  J Chad Hoyle; Courtney Jablonski; Herbert B Newton
Journal:  Neurohospitalist       Date:  2014-04

Review 9.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

10.  Isolated Bulbar Palsy: A Rare Presentation of Neurosarcoidosis.

Authors:  Hammad S Chaudhry; Fateen Ata; Mohamed Abdelghani; Rashid Kazman; Ali Rahil
Journal:  Cureus       Date:  2020-02-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.